anlotinib

Overview

Anlotinib is an oral multi-target tyrosine kinase inhibitor (TKI) targeting VEGFR2 (KDR), FGFR1, PDGFRA, and KIT, among others. It has anti-angiogenic activity and has been investigated in multiple solid tumor types including hepatocellular carcinoma (HCC) and nasopharyngeal carcinoma (NPC).

Evidence in the corpus

• Cited among VEGFR-targeting anti-angiogenic agents under investigation in HCC PMID:24798001.
• Cited as a multi-target anti-angiogenic TKI among agents under clinical investigation for R/M NPC PMID:24952746.
• Cited in the context of sintilimab+anlotinib combination therapy for biliary tract cancer (BTC), whose efficacy is modulated by gut microbiota composition (Proteobacteria dominance reduces outcomes) PMID:25608663

Resistance mechanisms

Cancer types (linked)

• HCC
• NPC

Sources

This page was processed by crosslinker on 2026-05-14. - PMID:25608663

This page was processed by crosslinker on 2026-05-14.